Business
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026 Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting Cash and investments of $926 million as of December
About this update from Praxis Precision Medicines, Inc.
[{"type":"image","alt":"Praxis Precision Medicines, Inc.","displaySize":"","headline":null,"caption":"Praxis Precision Medicines, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/605fef7bcd4287efde06f3c1abced879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gfuDyxXigQjbpaazoPvi_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/605fef7bcd4287efde06f3c1abced879","width":300,"height":117}},"lazy":false},{"type":"text","content":"Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA)","length":239,"tagName":"p"},{"type":"text","content":"Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026","length":102,"tagName":"p"},{"type":"text","content":"Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting","length":110,"tagName":"p"},{"type":"text","content":"Cash and investments of $926 million as of December 31, 2025 and net proceeds of $621 million from January 2026 public offering fund operations into 2028Conference call today, February 19, 2026 at 8:00 am E.T.","length":210,"tagName":"p"},{"type":"text","content":"BOSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full-year 2025.","length":305,"tagName":"p"},{"type":"text","content":"“After a landmark fourth quarter, filled with a breadth of clinical and regulatory advancements across our portfolio, we started 2026 with two NDA submissions for ulixacaltamide and relutrigine. Pending their expected positive reviews, we will be positioned to transition into a commercial company,” said Marcio Souza, president and chief executive officer. “The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years. Together, th...